126 related articles for article (PubMed ID: 38593267)
1. Bioequivalence of Elagolix/Estradiol/Norethindrone Acetate Fixed-Dose Combination Product: Phase 1 Results in Healthy Pre- and Postmenopausal Women.
Chen MJ; Marroum P; Chiu YL; Neenan M; Mostafa NM; Shebley M
Clin Pharmacol Drug Dev; 2024 Jun; 13(6):601-610. PubMed ID: 38593267
[TBL] [Abstract][Full Text] [Related]
2. Drug-Drug Interaction Studies of Elagolix with Oral and Transdermal Low-Dose Hormonal Add-Back Therapy.
Nader A; Mostafa NM; Ali F; Shebley M
Clin Pharmacokinet; 2021 Jan; 60(1):133-143. PubMed ID: 32696440
[TBL] [Abstract][Full Text] [Related]
3. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.
Simon JA; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Dayspring T; Feinberg EC; Gillispie V; Hurtado S; Kim J; Liu R; Owens CD; Muneyyirci-Delale O; Wang A; Watts NB; Schlaff WD
Obstet Gynecol; 2020 Jun; 135(6):1313-1326. PubMed ID: 32459423
[TBL] [Abstract][Full Text] [Related]
4. Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.
Carr BR; Stewart EA; Archer DF; Al-Hendy A; Bradley L; Watts NB; Diamond MP; Gao J; Owens CD; Chwalisz K; Duan WR; Soliman AM; Dufek MB; Simon JA
Obstet Gynecol; 2018 Nov; 132(5):1252-1264. PubMed ID: 30303923
[TBL] [Abstract][Full Text] [Related]
5. Virtual Bioequivalence Assessment of Elagolix Formulations Using Physiologically Based Pharmacokinetic Modeling.
Mukherjee D; Chen MJ; Shao X; Ju TR; Shebley M; Marroum P
AAPS J; 2023 Mar; 25(3):30. PubMed ID: 36949256
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist.
Polepally AR; Ng JW; Salem AH; Dufek MB; Parikh A; Carter DC; Kamradt K; Mostafa NM; Shebley M
J Clin Pharmacol; 2020 Dec; 60(12):1606-1616. PubMed ID: 33045114
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence and relative bioavailability of three estradiol and norethisterone acetate-containing hormone replacement therapy tablets.
Zdravkovic M; Müller M; Larsen S; Degenkolb J; Pabst G
Int J Clin Pharmacol Ther; 2001 Jan; 39(1):41-6. PubMed ID: 11204938
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms.
Saure A; Hirvonen E; Milsom I; Christensen A; Damber MG
Maturitas; 1996 May; 24(1-2):111-8. PubMed ID: 8794442
[TBL] [Abstract][Full Text] [Related]
9. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.
Schlaff WD; Ackerman RT; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Feinberg EC; Hurtado SM; Kim J; Liu R; Mabey RG; Owens CD; Poindexter A; Puscheck EE; Rodriguez-Ginorio H; Simon JA; Soliman AM; Stewart EA; Watts NB; Muneyyirci-Delale O
N Engl J Med; 2020 Jan; 382(4):328-340. PubMed ID: 31971678
[TBL] [Abstract][Full Text] [Related]
10. Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Ali M; A R S; Al Hendy A
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):427-437. PubMed ID: 33682578
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids.
Beck D; Winzenborg I; Liu M; Degner J; Mostafa NM; Noertersheuser P; Shebley M
Clin Pharmacokinet; 2022 Apr; 61(4):577-587. PubMed ID: 34878624
[TBL] [Abstract][Full Text] [Related]
12. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.
Archer DF; Stewart EA; Jain RI; Feldman RA; Lukes AS; North JD; Soliman AM; Gao J; Ng JW; Chwalisz K
Fertil Steril; 2017 Jul; 108(1):152-160.e4. PubMed ID: 28579415
[TBL] [Abstract][Full Text] [Related]
13. Bioavailability of norethisterone acetate alone and in combination with estradiol administered in single or multiple oral doses to postmenopausal women.
Stadberg E; Westlund P; Landgren BM; Aedo AR; Cekan SZ; Mattsson LA
Maturitas; 1999 Sep; 33(1):59-69. PubMed ID: 10585174
[TBL] [Abstract][Full Text] [Related]
14. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix.
Struthers RS; Nicholls AJ; Grundy J; Chen T; Jimenez R; Yen SS; Bozigian HP
J Clin Endocrinol Metab; 2009 Feb; 94(2):545-51. PubMed ID: 19033369
[TBL] [Abstract][Full Text] [Related]
15. Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis.
Muhammad J; Yusof Y; Ahmad I; Norhayati MN
BMC Womens Health; 2022 Jan; 22(1):14. PubMed ID: 35033041
[TBL] [Abstract][Full Text] [Related]
16. Elagolix Suppresses Ovulation in a Dose-Dependent Manner: Results From a 3-Month, Randomized Study in Ovulatory Women.
Archer DF; Ng J; Chwalisz K; Chiu YL; Feinberg EC; Miller CE; Feldman RA; Klein CE
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31650182
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109.
Pohl O; Marchand L; Fawkes N; Gotteland JP; Loumaye E
J Clin Endocrinol Metab; 2018 Feb; 103(2):497-504. PubMed ID: 29216361
[TBL] [Abstract][Full Text] [Related]
18. Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women.
Kimmerle R; Heinemann L; Heise T; Bender R; Weyer C; Hirschberger S; Berger M
Menopause; 1999; 6(1):36-42. PubMed ID: 10100178
[TBL] [Abstract][Full Text] [Related]
19. Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17beta-estradiol/trimegestone versus 1 or 2 mg 17beta-estradiol/norethisterone acetate in postmenopausal women.
Bouchard P; De Cicco-Nardone F; Spielmann D; Garcea N;
Gynecol Endocrinol; 2005 Sep; 21(3):142-8. PubMed ID: 16353319
[TBL] [Abstract][Full Text] [Related]
20. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids.
Al-Hendy A; Bradley L; Owens CD; Wang H; Barnhart KT; Feinberg E; Schlaff WD; Puscheck EE; Wang A; Gillispie V; Hurtado S; Muneyyirci-Delale O; Archer DF; Carr BR; Simon JA; Stewart EA
Am J Obstet Gynecol; 2021 Jan; 224(1):72.e1-72.e50. PubMed ID: 32702363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
